Clinical Trials Logo

Geographic Atrophy clinical trials

View clinical trials related to Geographic Atrophy.

Filter by:
  • Active, not recruiting  
  • Page 1 ·  Next »

NCT ID: NCT05963646 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Optical Coherence Tomography and Microperimetry Biomarker Evaluation in Patients With Geographic Atrophy Study

OMEGA
Start date: March 16, 2021
Phase:
Study type: Observational

This study is a biomarker evaluation study in patients with geographic atrophy secondary to age-related macular degeneration (AMD). The study evaluates microperimetry (fundus-controlled perimetry) and optical coherence tomography imaging for assessing changes in retinal sensitivity and anatomy over time.

NCT ID: NCT05536297 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy

Start date: September 26, 2022
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess long-term safety of avacincaptad pegol intravitreal administration for patients with geographic atrophy (GA) who completed Study ISEE2008 (GATHER2) through the Month 24 visit on study treatment (either avacincaptad pegol or Sham).

NCT ID: NCT05391074 Active, not recruiting - Clinical trials for Age-Related Macular Degeneration

Oral Postbiotics in Patients With Macular Atrophy

REVERS-GA
Start date: December 1, 2020
Phase: N/A
Study type: Interventional

A pilot study to evaluate the safety and efficacy of oral therapy with Postbiotics in patients with geographic atrophy secondary to age-related macular degeneration, myopia, or angioid streaks.

NCT ID: NCT05380492 Active, not recruiting - Clinical trials for Age-related Macular Degeneration

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Start date: November 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This safety study comprises a dose escalation study of VOY-101, followed by a cohort of subjects randomized to the maximum tolerated dose arm, a lower dose arm, and control arm.

NCT ID: NCT05019521 Active, not recruiting - Geographic Atrophy Clinical Trials

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Start date: August 23, 2021
Phase: Phase 2
Study type: Interventional

This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.

NCT ID: NCT04770545 Active, not recruiting - Clinical trials for Geographic Atrophy Secondary to Age-related Macular Degeneration

An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD

GALE
Start date: March 4, 2021
Phase: Phase 3
Study type: Interventional

This is a phase 3, open-label, multicenter, extension study to evaluate the long-term safety and efficacy of pegcetacoplan (APL-2) in subjects with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) who participated in Study APL2-103 (NCT03777332) or completed the treatment at Month 24 of either Study APL2-303 (Derby, NCT03525613) or Study APL2-304 (Oaks, NCT03525600).

NCT ID: NCT04676854 Active, not recruiting - Geographic Atrophy Clinical Trials

Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD

PRIMAvera
Start date: November 24, 2020
Phase: N/A
Study type: Interventional

The objective of this study is to evaluate the efficacy and safety of the PRIMA System in patients with atrophic AMD. Eligible subjects will be implanted with the PRIMA Implant. The subjects will be assessed with various visual function and functional vision tests at defined timepoints throughout the clinical investigation with the PRIMA System (Implant and Visual Processor).

NCT ID: NCT04656561 Active, not recruiting - Geographic Atrophy Clinical Trials

A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy

ARCHER
Start date: February 26, 2021
Phase: Phase 2
Study type: Interventional

This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate. The results will be used to guide further development of ANX007 in participants with geographic atrophy. The total duration of participation is expected to be approximately 19 months.

NCT ID: NCT04566445 Active, not recruiting - Clinical trials for Dry Age-related Macular Degeneration

HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

Start date: September 28, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration (AMD).

NCT ID: NCT04437368 Active, not recruiting - Clinical trials for Dry Age-related Macular Degeneration

EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005

EXPLORE
Start date: July 14, 2020
Phase: Phase 2
Study type: Interventional

The purpose of this clinical study is to evaluate the safety and efficacy of two doses of GT005 administered as a single subretinal injection in subjects with geographic atrophy secondary to age-related macular degeneration (AMD).